BQ-788
Also known as: B-788, BQ‑788, BQ788, ETB receptor antagonist BQ-788, N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine
Source BQ-788 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
BQ‑788 is a cyclic peptide antagonist that selectively blocks ET_B receptors. It is used primarily in pre‑clinical and early clinical studies to explore the role of ET_B signaling in cardiovascular, renal and pulmonary diseases.
Mechanism of Action
Competitive antagonism of the endothelin B receptor, blocking endothelin‑1–mediated vasoconstriction, cell proliferation and natriuretic signaling.
Routes of Administration
Goals & Uses
- Pain and nociception researchNeuroscience ResearchLow
- Vascular tone researchCardiovascular ResearchModerate
- Pulmonary hypertension researchCardiovascular ResearchLow
- Fibrosis attenuationFibrotic DiseasesLow
- Renal protectionRenalModerate
- Pulmonary hypertensionCardiovascularModerate
- Endothelin system dissectionPharmacological ToolHigh
- Tumor vasculature modulationOncology ResearchLow
Contraindications
- Clinical therapeutic useRegulatoryHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- Blood pressure elevationCardiovascularUnknown
- Injection site reactionsLocalUnknown
- HypotensionCardiovascularUncommonLow blood pressure
- TachycardiaCardiovascularUncommonAbnormally fast heart rate
- VasoconstrictionCardiovascularUnknown
Drug Interactions
- BQ-123 (ET-A antagonist)Moderate
- Endothelin-1Low
Population Constraints
- General human population (therapeutic)Regulatory ConstraintAbsolute
- Pregnant subjectsReproductiveRelative
Regulatory Status
- European UnionInvestigationalUsed in clinical trial settings.
- United StatesInvestigationalAvailable only for IND‑supported research.
- United KingdomInvestigationalResearch use only.
BQ-788 has no regulatory approval in any jurisdiction. It is used exclusively as a research compound in preclinical and some early clinical investigational studies.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is BQ-788?
BQ‑788 is a cyclic peptide antagonist that selectively blocks ET_B receptors. It is used primarily in pre‑clinical and early clinical studies to explore the role of ET_B signaling in cardiovascular, renal and pulmonary diseases.
What is BQ-788 used for?
BQ-788 is educationally associated with: Pain and nociception research, Vascular tone research, Pulmonary hypertension research, Fibrosis attenuation, Renal protection, Pulmonary hypertension, Endothelin system dissection, Tumor vasculature modulation. Educational only — not medical advice.
How is BQ-788 administered?
Recorded routes of administration: Intracoronary, Intraperitoneal, Intrathecal, Intravenous, Subcutaneous.
What are the potential side effects of BQ-788?
Reported adverse effects include: Blood pressure elevation, Injection site reactions, Hypotension, Tachycardia, Vasoconstriction. This list is not exhaustive — consult a qualified clinician.
Who should avoid BQ-788?
Recorded contraindications: Clinical therapeutic use, Pregnancy. Consult a qualified clinician before use.